25Jul/13

The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As … – The Providence Journal

The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As
The Providence Journal
be followed by the emergence of more-convenient reformulations of platform injectables and three highly efficacious monoclonal antibodies– Genzyme/Bayer HealthCare’s Lemtrada, Roche/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s daclizumab.

25Jul/13

The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As … – PR Newswire (press release)

The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As
PR Newswire (press release)
be followed by the emergence of more-convenient reformulations of platform injectables and three highly efficacious monoclonal antibodies— Genzyme/Bayer HealthCare’s Lemtrada, Roche/Genentech’s ocrelizumab and Biogen Idec/AbbVie’s daclizumab.

and more »